FDA Approves Dupixent for Treatment of Bullous Pemphigoid
The FDA has approved Dupixent for adult patients with bullous pemphigoid, offering a new targeted treatment option based on promising clinical trial results that show improved remission and reduced itch.
The U.S. Food and Drug Administration has granted approval for Dupixent (dupilumab) to be used in treating adult patients suffering from bullous pemphigoid, a chronic autoimmune skin condition characterized by large, tense blisters. The approval was based on compelling results from the ADEPT phase 2/3 clinical trial, which demonstrated significant benefits for patients.
In the study, individuals with moderate-to-severe bullous pemphigoid were randomly assigned to receive either Dupixent 300 mg or a placebo, both added to standard oral corticosteroid therapy. After 36 weeks, 18.3% of those treated with Dupixent achieved sustained disease remission, compared to only 6.1% in the placebo group. Moreover, 38.3% of patients on Dupixent experienced a meaningful reduction in itch severity, a common and distressing symptom, versus 10.5% on placebo. The treatment also allowed for a lower median cumulative dose of oral corticosteroids (2.8 grams with Dupixent vs. 4.1 grams with placebo), indicating a potential to reduce steroid-related side effects.
Patients receiving Dupixent commonly experienced adverse events such as joint pain, conjunctivitis, blurred vision, herpes viral infections, and keratitis. There was also a case of acute generalized exanthematous pustulosis reported. Despite these side effects, experts highlight the importance of this therapeutic advance, especially considering the challenges of managing bullous pemphigoid in elderly populations who often face additional health burdens.
Alyssa Johnsen, M.D., Ph.D., from Sanofi, noted that until now, treatment options for bullous pemphigoid have been limited and often problematic. She emphasized that Dupixent uniquely targets key mechanisms underlying the disease, addressing the type 2 inflammation central to its pathology, which may enable patients to achieve sustained remission and experience less itching.
The approval was a collaborative effort between Sanofi and Regeneron, marking a significant step forward in targeted therapy for autoimmune skin disorders.
For more details, see the original report at MedicalXpress.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Young Children Can Learn Words Despite Masked Speakers
Research shows that children from age two can acquire new vocabulary even when speakers wear masks or coverings, emphasizing the importance of social cues beyond facial visibility in early language development.
Mediterranean Diet May Not Enhance Brain Health Across All Aging Populations
Recent research shows that while the Mediterranean diet promotes weight loss and metabolic health, its effects on cognitive function may vary among different aging populations. Longer studies are needed.
Texas Woman Dies After Using Tap Water in Sinus Rinse
A Texas woman tragically died after using tap water in a sinus rinse, leading to a rare brain infection caused by Naegleria fowleri. Health officials warn about water safety practices during nasal irrigation.
Breakthrough in Gene Editing Offers Potential Treatment for Smooth Muscle Diseases
Researchers at UT Southwestern have used advanced gene editing techniques to successfully treat a rare, inherited smooth muscle disorder in preclinical models, paving the way for potential innovative therapies.